

Management of Anaemia reduces Red cell Transfusion in NI

Dr Susan Atkinson
NI Transfusion Committee



NI Red Cell Issues

2000 - 2008



Regional Audit of Red Cell Transfusions 2004-2005

Transfusion Triggers


Hb < 7 g/dl: < 65 yr, no CVS disease


Hb < 8 g/dl: > 65 yr, no CVS disease

Hb < 9 g/dl: CVS disease

Hb < 10 g / dl
Bone marrow depression
Chemo or radiotherapy
Symptomatic of anaemia
Ongoing bleeding > 500 ml / hr

1220 transfusion episodes





Audit Recommendations Endorsed

DHSSPS 2006

From the Chief Medical Officer **Dr Michael McBride**



Sláinte, Seirbhísí Sóisialta agus Sábháilteachta Poiblí

www.dhsspsni.gov.uk

To:

Medical Directors of Trusts – for transmission to all hospital doctors and doctors in Community Trusts who may prescribe blood transfusion.

Directors of Nursing of Trusts – for attention of Nursing and Midwifery staff.

Castle Buildings Stormont Estate Belfast BT4 3SQ Tel: 028 90 520563 Fax: 028 90 520574

Email:michael.mcbride@dhsspsni.gov.uk

Your Ref:

Date: 17 November 2006

Dear Colleagues

APPROPRIATE USE OF BLOOD IN NORTHERN IRELAND

You may remember that CREST guidelines on the use of blood in Northern Ireland were distributed in 2001. Following this, the Northern Ireland Regional Transfusion Committee undertook a major audit of red cell use in Northern Ireland¹. This was supported by RMAG.


The results of this audit were presented at a Workshop earlier this year. It is fair to say that the results were disappointing, with a considerable proportion of blood use in Northern Ireland being judged inappropriate.

Because of the increased risk that blood transfusion now carries, not least the danger of communicable disease that has not yet been identified, and the fact that every recipient of blood is now automatically barred from ever donating blood, CREST has drawn up new guidelines on blood transfusion in adult patients, and these are currently out for consultation.

However, I wanted to draw your attention to the major points in the new guidelines, as quickly as possible.

Transfusion thresholds:

- For otherwise healthy patients less that 65 years of age a transfusion trigger of 7g/dl is appropriate.
- For otherwise healthy patients over 65 years of age a transfusion trigger of 8g/dl is appropriate.
- For otherwise healthy patients with additional risk factors of cardiac and cerebrovascular insufficiency, a higher trigger of 9g/dl is permitted.



Regional Guidance 2009



BETTER USE OF BLOOD IN NORTHERN IRELAND

Guidelines for Blood Transfusion Practice

March 2009

Guidelines for Red Cell Transfusion (Adults)

- Always diagnose the cause of anaemia
- Treat reversible causes of angemia

Stable Patients	Transfusion Threshold
< 65 years old with no cardiovascular or cerebrovascular problems.	Usually only consider transfusion when Hb < 7g/dl
> 65 years old with no cardiovascular or cerebrovascular problems.	Usually only consider transfusion when Hb < 8g/dl
Known cardiovascular or cerebrovascular history (previous myocardial infarction, angina, hypertension, heart failure, peripheral vascular disease pulmonary oedema).	Usually only consider transfusion when Hb < 9g/dl


Patients with symptoms due to anaemia Unstable patients bleeding heavily Impaired marrow function	Transfusion Threshold	
Symptoms (dyspnoea, angina, palpitations, tachycardia, orthostatic hypotension, syncope) likely to be due to the anaemia.	Consider transfusion when Hb < 10g/dl	
Note - Tiredness alone is not an appropriate symptom for transfusion		
Documented/obvious evidence of ongoing significant bleeding at time of transfusion causing symptoms as above or bleeding more than 500ml per hour and not stopping.	Consider transfusion when Hb < 10g/dl	
Current or recent (within 3 months) marrow failure or chemotherapy or radiotherapy.	Consider transfusion when Hb < 10g/dl	

Patients should only be transfused to a target of 2.0g/dl haemoglobin in excess of the chosen threshold for transfusion above.

Consider patient's estimated blood volume and any ongoing bleeding.



Regional Blood Request Form




Zero tolerance


Indication for transfusion




NI Red Cell Issues 2000 – 2008




No. of Units per 1000 population





Haemoglobin at time of Hospital Admission

Regional audit 2004 - 2006




Haemoglobin on admission g/l


> 85% Anaemic


WHO Definition of anaemia

Adult female < 120 g/l

Adult male < 130 g/l










Regional Audit of Anaemic patients



743 anaemic patients, 16 yr and older Transfused in 2007

Retrospective review of patients' notes laboratory reports, outpatient letters, discharge summaries

Was anaemia identified?


Was anaemia investigated and diagnosed?

Was anaemia treated appropriately?


Haemoglobin on admission



Transfused Patients - Haemoglobin on Hospital Admission by Gender









Mean 69 years

Median 73 years






Mean 68 years


Median 72 years


Regional audit of Anaemia Could transfusion have been avoided?

743 Patients




Avoidable Transfusions






Regional audit of Anaemia Could transfusion have been avoided?







Action Plan



Regional Pathway for investigation and treatment of anaemia

Results of Audit should be circulated

Educational presentation for Haemovigilance staff

Trusts should audit avoidable transfusion

Training should focus more on Investigation and Treatment of Anaemia

Guidelines for Transfusion are implemented and monitored.

Practice Improvement

Iron deficiend

assessment

Pre-operative

Regional Anaemia Study day

Increased awareness of at risk groups

Iron deficiency should be treated with oral or parenteral iron – not transfusion

"Anaemia: Old Problem, New Focus"

When and How should we treat Anaemia In Primary and Hospital Care

Thursday 25 February 2010 (09.45 – 16.00hr) Malone House Belfast

TIME	PRESENTATION	SPEAKER
09.45	Anaemia – an old problem: Historic Perspective	Prof M Murphy
		Cons Haematologist
10.00	Anaemia and the Patient with Ischaemic Heart Disease	Dr H Gilliland
		Cons Anaesthetist
10.20	Anaemia in Pregnancy	Dr Shubha Allard
	-	Cons Haematologist
10.30	Anaemia in the Critical Care Patient	Dr D McAuley
		Cons Anaesthetist
10.50	Rehabilitation of the Elderly Anaemic Patient	Dr G Heyburn
	,	Ortho Geriatrician
11.10	Discussion	
11.15	Coffee	
11.45	What do "Iron studies and other Laboratory tests tell us?	Mr T McFarland
	•	Senior Biomedical
		Officer
12.05	How does the body handle iron?	Dr Nicole Pridee
	-	SpR Haematology
12.25	Investigation of Anaemia by the Gastroenterologist	Dr S Johnston
		Cons
		Gastroenterologist
12.45	Investigation and management of non iron deficiency	Dr G Benson
	anaemia	Cons Haematologist
13.05	Discussion	
13.10	Lunch	
14.00	Preoperative Optimisation of Haemoglobin and Iron stores	Dr Craig Taylor
		Cons Haematologist
14.20	Haemoglobin and the Pre-assessment Clinic Experience	Ms Lynn Jones
		Pre-assessment nurse
14.40	Pre transfusion anaemia – Preventable Transfusion Audit	Dr D Carson
	report	Cons Anaesthetist
15.00	Discussion session: When and how to treat anaemia: scoping	Dr S Atkinson
15.30	exercise for regional guidance	
15.30	Meeting close	

Better Blood Transfusion 3 NI Improving the safety of blood transfusion

From the Chief Medical Officer Dr Michael McBride



Castle Buildings

Tel: 028 9052 0663

Fax: 028 9052 0574

Date: 24 August 2011

Errolt michael richtlichte gemilien und

Stormont

BELEAST BT4 38Q

HSS(MD) 17/2011

Chief Executive of HSC Trusts for distribution to:

- Medical Directors
- Directors of Nursing
- Chairs of Transfusion Committees
- Hospital Blood Banks
- Consultant Haematologists Haemovigilance Practitioners
- Chief Executive, ROIA for distribution to:
- Independent Hospitals, Hospicas and agencies providing blood Our Ref: HSS(MD) 17/2011 transfusions

Chief Executive, HSC Board for distribution to:

Director of Performance Management and Service Improvement Chief Executive, Public Health Agency for distribution to:

DPH/Medical Director.

Director of Nursing

Chief Executive of the NI Blood Transfusion Service Chair of NI Regional Transfusion Committee

For Information:

Postgraduate Medical Deen, NI Medical and Dental Training Agency Head of School of Medicine, Dentistry and Biomedical Sciences, OUB Head of School of Nursing and Midwilery, Queen's University Bellest Dean of Life and Health Sciences, University of Uister Chief Executive, Northern Ireland Practice & Education Council

Dear Colleague

BETTER BLOOD TRANSFUSION 3 NORTHERN IRELAND (BBT3 NI)

Introduction

This Circular and the attached Action Plan (see Annex) replace and build on the requirements of HSS(MD) 6/03 Better Blood Transfusion, and aim to promote safe and appropriate provision and transfusion of blood components and blood products. They take into account the requirements of the Blood Safety and Quality Regulations 2005 - Statutory Instrument 2005/50 and Blood Safety and Quality Amendment 2005 no. 2 (BSQR 2005), HSC (SQSD) 30/2007 which endorsed the NPSA Safer Practice Notice 14: Right Patient, Right Blood 2007 (NPSA SPN 14) and the recommendations in the RQIA Report of Blood Safety Review (2010).

- Circulated to HSC Trusts
 - Aug 2011
- Interim self assessment
 - Dec 2011
- Final assessment
 - Sept 2012

HSS(MD) 17/2011



Chief Executive of LISC Trusts for distribution to

- Medical Directors Directors of Nursing
- Chairs of Transfusion Committees
- Hospital Blood Banks
- Consultant Haematologists
- Haemovigliance Practitioners
- Chief Executive, RQIA for distribution to:
- Independent Hospitals, Hospices and agencies providing blood transfusions
- Chief Executive, HSC Board for distribution to: Director of Performance Management and Sendoe Improvement

Ceatte Buildings BT4 39Q

Tel: 028 9052 0563 Email: michael.mcbride@dhaspeni.gov.uk

Our Het. HSS(MD) 17/2011 Date: 24 August 2011

3. Reduction in Patient Requirement for Components or Products from Donated Blood

- 3.1 Trusts should promote early detection of anaemia. They should develop and implement local policies and procedures for the identification, investigation and treatment of anaemia (See GAIN guidance 2010, Management of Anaemia and Avoidance of Transfusion).
- 3.2 The NIRTC must develop regional guidance for the detection and management of anaemia, including the process of optimisation of haemoglobin prior to scheduled surgery.
- 3.3 Healthcare Staff who work in pre-assessment clinics should liaise with Healthcare Professionals in primary care and hospitals to correct iron deficiency anaemia and optimise haemoglobin and haemostasis prior to scheduled surgical or other invasive procedures.

Management of Anaemia 4 – Step approach

4 STEPS IN THE INVESTIGATION AND MANAGEMENT OF THE ADULT PATIENT WITH ANAEMIA

STEP 1

Test full blood picture for Haemoglobin (Hb) and mean corpuscular haemoglobin (MCV)

If Hb below normal range follow steps below

STEP 2

MCV low - perform iron studies (including serum ferritin)

MCV normal range - check iron studies, renal function, serum folate and vitamin B12 levels

MCV high - check liver function tests, thyroid function, serum folate and vitamin B12 levels

STEP 3

1. Start appropriate corrective therapy for anaemia without delay (e.g. oral iron therapy)

AND

 Investigate cause of anaemia unless already known or further investigation is not in patient's best interests (e.g. palliative care only)

STEP 4

Monitor response to corrective therapy for anaemia, including rise in Hb.

AND

2. Treat the cause of anaemia (e.g. surgery for carcinoma of bowel)

WHO Classification of anaemia

Haemoglobin: < 13 g/dl in adult male

< 12 g/dl in adult female

< 11 g/dl in pregnancy

Abbreviations used:

CRP: C-reactive protein

TIBC: total iron binding capacity

TSAT: transferrin saturation

LFTs: liver function tests

ESA: erythrocyte stimulating factor or recombinant erythropoietin

eGFR: estimated glomerulofiltration rate

Sickle cell disease – perform Sickledex test if positive family history or patient's genetic origin is West Africa

MICROCYTIC ANAEMIA

STEP 1

Full Blood Picture Test

**MCV < 76fl or MCH <27pa Microcytic anaemia

**Normal range values may differ between hospital laboratories

STEP 2

- Iron studies (include se ferritin and TIBC)
- CRP

STEP 3:

STEP 4:

- Correct anaemia
- Investigate cause if unknown (unless further investigation not in patient's best interests)

Se ferritin < 30 mca/l when CRP < 30 mg/l Se ferritin < 70 mcg/l when CRP > 30 mg/l TIBC increased

Manage as IRON DEFICIENCY ANAEMIA

IRON DEFICIENCY ANAEMIA

- a) Start oral iron therapy to normalise Hb and replenish iron stores Start with parenteral iron therapy if:
 - History of oral iron intolerance or poor compliance
 - Impaired gastrointestinal absorption
 - Haemodialysis
 - Major surgery must take place in < 3 weeks
- b) Review history & examination for source of chronic bleeding. Refer to gastroenterologist if
 - Adult male
 - Postmenopausal female
- Premenopausal female with gastro-intestinal symptoms or bleeding
- NB oral Iron therapy must be suspended for 1 week prior to colonoscopy

Refer to gynaecologist if

- Post menopausal bleeding
- Menorrhagia

Monitor response to replacement therapy

Treat disease causing the anaemia

Perform FBP after 3 weeks of iron therapy If improvement in Hb (10-20 g/l increase):

- Check if Hb normalised after 2-4 months iron therapy
- Continue iron therapy for another 3 months to replenish iron stores.

If no improvement, consider:

Switch to parenteral iron therapy.

MICROCYTIC ANAEMIA NOT DUE TO IRON DEFICIENCY

Se ferritin > 70 mcg/l, CRP normal or increased

TIBC normal or decreased

Go to STEP 3

Assess for acute or chronic inflammatory disease, chronic infection, malignancy and liver disease - check differential WCC. LFTs

If thalassaemia or sideroblastic anaemia suspected or cause of anaemia unknown refer to a haematologist

IRON DEFICIENCY ANAEMIA

A diagnosis of exclusion Unresponsive to parenteral iron unless iron deficiency also present


ANAEMIA OF CHRONIC DISEASE


Treat and monitor the underlying cause

INVES

Drugs and Therapeutics Committee Detection, Invest

NORMOCYTIC ANAEMIA





From the Chief Medical Officer
Dr Michael McBride

HSS(MD) 22/2012

Circulation list:

For Action:

Chief Executives of HSC Trusts
Medical Directors of HSC Trusts
(for onward distribution to All Hospital Doctors)
Director of Integrated Care, Health and Social Care Board
All General Practitioners
GP Locums
Family Practitioner Service Leads, HSC Board
(for cascade to GP Out of Hours services)
Directors of Nursing of HSC Trusts
(for cascade to nursing staff)



Castle Buildings Stormont BELFAST BT4 3SQ

Tel: 028 9052 0563 Fax: 028 9052 0574

Email: michael.mcbride@dhsspsni.gov.uk

Your Ref:

Our Ref: HSS(MD) 22/2012 Date: 11 June 2012

DETECTION, INVESTIGATION AND MANAGEMENT OF ANAEMIA

- The purpose of this letter is to disseminate two new guidance documents on the detection, investigation and management of anaemia. The documents are:
 - FOUR STEPS IN THE INVESTIGATION AND MANAGEMENT OF THE ADULT PATIENT WITH ANAEMIA
 - ii. MANAGEMENT OF THE ANAEMIC ADULT PATIENT PRIOR TO SCHEDULED MAJOR SURGERY

MANAGEMENT OF THE ANAEMIC ADULT PATIENT PRIOR TO SCHEDULED MAJOR SURGERY

(Also applicable to other invasive procedures with potential for blood loss)
WHO definition of anaemia²: adult male < 130g/l adult female < 120g/l

Pre assess patient at least 4-6 weeks before surgery Assess medical and drug history Test Full Blood Picture – if anaemic see below

Additional blood tests to determine type of anaemia

- Serum ferritin
- TIBC
- Urea & electrolytes
- Liver function tests
- · Serum folate and
- Vitamin B12 levels

Investigate cause of anaemia

- Refer to clinical specialist (e.g. gastroenterologist) unless:
- The cause has already been identified

or

 It is not in the patient's best interests (e.g. palliative care patient)

Medication and other substances taken by patient

- Note which drugs and other substances (e.g. herbal remedies) could increase perioperative blood loss
- Advise patient to discontinue herbal remedies 2 weeks before surgery

Follow 4 Steps algorithm for subsequent management of the anaemic patient

Correct anaemia without delay

- Prescribe appropriate replacement therapy
- Monitor response to treatment after 3 weeks
- Continue or adjust therapy as appropriate
- Aim to have Hb in normal range before surgery³.
- Delay date of surgery, unless it is not in the patient's best interests

Treat the cause of anaemia

- Refer to appropriate clinical specialist for treatment as appropriate
- For newly detected anaemia it may be beneficial to fully evaluate the cause and associated clinical status before major surgery is undertaken²

Reduce perioperative blood loss

- Discontinue NSAIDs 24 hr preoperatively
- Consider risks vs benefits of preoperative discontinuation of anti platelet drugs (e.g. clopidogrel)
- Consider preoperative switch from warfarin to:
- Low dose prophylactic LMWH or
- Bridging therapy with therapeutic LMWH (seek local guidance + expert advice)

Patient Blood Management



Volume 108, Number 6, June 2012

British Journal of Ancesthesia 108 (6): 889-92 (2012) doi:10.1093/bja/ces166

EDITORIAL

Patient blood management is a win-win: a wake-up call

D. R. Spahn^{1*}, O. M. Theusinger² and A. Hofmann³

¹Institute of Anaesthesiology, Section of Anaesthesiology, Intensive Core Medicine and OR-Management, University Haspital Zurich, Zurich OH-8091, Switzerland

³Institute of Anaesthesiology, University Hospital Zurich, Zurich CH-8091, Switzerland ³Faculty of Health Sciences, Curtin University, Perth, Australia

* Corresponding outhor, E-mail: donat.spohn@usz.ch

Review Astrone

Assettantidografica, 114-042-95

Anemia and Patient Blood Management in Hip and Knee Surgery

A Systematic Review of the Literature

Bonat R. Spahn, M.D., F.R.C.A.*



This article has been selected for the Aventoscoor CME Program. Learning objectives and disclosure and ordering information can be found in the GMC section at the Fort of this issue.

ABSTRACT

A systematic search was conducted to determine the characteristics of perioperative attention is association with clinical con-

Wedness and Cultures, Institute of Americanhology, University Hospital and University of Zurich, Zurich, Automatical.

Remarks from the best to of Americaning, University Mounts and Decompt of Tallows, Service States, Americania, Individual for politicism Normalian 13, 2004. Accorded to politicism the best and J. 2004. Accorded to politicism the the size, A. 2004. Accorded to politicism the the size, A. 2004. Accorded to politicism the theorem that the politicism for the size of t

more, and the offers of positive bland resuggences increased to a not these concentration products are designed; analysis, in patients analogouing such also or large arthopology and high contrast analogouing such high products, analogo from 24 – 90 in 442 – 90, anaporticly. Netoportal-resuman was over rance products 1910s and 7 \pm 10%, anaporticly. Netoportal-resuman was over rance products 1910s and with a blood translation rate of 90 \pm 29% and 44 \pm 10%, appear positive inferrious, power piputed inferrious and an execution with a blood translation rate of 90 \pm 29% and 44 \pm 10%, appear positive inferrious, power piputed inferrious and increased inspire of hospital any and mornality. Translation of increased inspired on the such time, with or without coupling and according to the contrast of posseparity as active with two, with or without coupling increase of the contrast of the contrast of an experiment of an experiment of the contrast of posseparity as active with two to improve of points concretely. High-begans prospective such in the recessing to design the such as the constant or the contrast of the con

P [87] and prosperative areas is highly provides in suringle parison. Among parisons are more Holy in motion allogated board conditions of ART (the accountparison. ART the short suggested that prosperative assessinal increased ART was some independents. Are successed, such as increased prosperative adverse excusses, such as increased prosperative inferious, increased hospital length of target (2003, and increased meaning 1974).

Assumey of the demographics of blood use insteach England in the year 2000 showed that 20% of the enterfaced blood units see given so medical justices. A 5th is surpol justices, and the remainder to obserticantly generology parties. Major orthogo-

British Journal of Anaesthesia 106 (8): 943–52 (2012) dai:10.1093/bja/aes135

BJA

CLINICAL PRACTICE

Effect of a patient blood management programme on preoperative anaemia, transfusion rate, and outcome after primary hip or knee arthroplasty: a quality improvement cycle¹¹

A. Kotzė1*, L. A. Carter1 and A. J. Scally2

- ¹ Alredale NHS Foundation Trust, Steeton, UK
- ² School of Health Studies, University of Bradford, Bradford, UK
- * Corresponding author: Department of Anaesthesia, Leeds General Infirmary, Great George Street, Leeds LS1 3EX, UK

E-mail: alwynkotze@doctors.net.uk

Editor's key points

- Perioperative anaemia is associated with worse autoomes after major joint replacement.
- This paper reports on active blood management programme, including measures to detect and tead anaemia several weeks before elective primary hip or knee replacement.
- After the introduction of the programme, significant improvements in outcomes were found, with the potential to save costs.

Background. There are few data on the associations between anaemia, allogeneic blood transfusion (ABT), patient blood management, and outcome ofter orthroplasty in the UK. National agencies nevertheless instruct NHS Trusts to implement blood conservation measures including preoperative anaemia management. Internationally, blood management programmes show encouraging results.

Methods. We retrospectively audited 717 primary hip or knee arthroplasties in a UK general hospital and conducted regression analyses to identify outcome predictors. We used these data to modify previously published algorithms for UK practice and audited its introduction prospectively. The retrospective audit group served as a control.

Results Respective hormoglobin-0-bit concentration predicted AIII (adds ratio 0.25 per 1 gdf⁻¹, P=0.004). It also predicted the length of stay ILOS, effect size -0.7 days per 1 g df⁻¹, P=0.004, independently of ABT, including in non-encentic potients. Patient blood management implementation was associated with lower AIII rates for hig (3)=748, P=0.009) and knee (T=08, P=0.001) and knee (T=08, P=0.001) and knee replacement decreased from 6 (5–8) days to 5 (3–7) and 4 (3–6) days, respectively, after algorithm implementation P=0.001), the oil-cause re-admission rate within 90 days decreased from 13-36 (9/17) before to 8.256 (2304III) dates objectively might be seen to P=0.002,

Conclusions. We conclude that preoperative Hb predicts markers of orthroplasty outcome in UK practice. A systematic approach to optimize Hb mass before arthroplasty and limit Hb loss perioperatively was associated with improved outcome up to 90 days after discharge.

1st Pillar Optimise erythropoiesis

2nd Pillar Minimise blood loss & bleeding

3rd Pillar

Harness & optimise physiological reserve of anaemia

- Detect anaemia
- Identify underlying disorder(s) causing anaemia
- Manage disorder(s)
- Refer for further evaluation if necessary
- Treat suboptimal iron stores/iron deficiency/anemia of chronic disease/iron-restricted erythropoiesis
- · Treat other haematinic deficiencies
- Note: Anaemia is a contraindication for elective surgery
- Timing surgery with haematological optimisation

- Stimulate erythropoiesis
- Be aware of drug interactions that can increase anaemia

- Identify and manage bleeding risk
- Minimising iatrogenic blood loss
- Procedure planning and rehearsal
- Preoperative autologous blood donation (in selected cases or when patient choice)
- Other
- Meticulous haemostasis and surgical techniques
- · Blood-sparing surgical techniques
- Anaesthetic blood conserving strategies
- · Autologous blood options
- Pharmacological/haemostatic agents
- Vigilant monitoring and management of post-operative bleeding
- · Avoid secondary haemorrhage
- Rapid warming / maintain normothermia (unless hypothermia specifically indicated)
- Autologous blood salvage
- Minimising iatrogenic blood loss
- Haemostasis/anticoagulation management
- Prophylaxis of upper GI haemorrhage

medication


- Avoid/treat infections promptly
- Be aware of adverse effects of

- Assess/optimise patient's physiological reserve and risk factors
- Compare estimated blood loss with patient-specific tolerable blood loss
- Formulate patient-specific management plan using appropriate blood conservation modalities to minimise blood loss, optimise red cell mass and manage anaemia
- Restrictive transfusion thresholds
- Optimise cardiac output
- Optimise ventilation and oxygenation
- · Restrictive transfusion thresholds

Optimise anaemia reserve
Maximise oxygen delivery

- Minimise oxygen consumption
- Avoid/treat infections promptly
- Restrictive transfusion thresholds


Red Cell Transfusion Index 2011 - 2014



NI Transfusion Index

(12 monthly moving average)

Units transfused / 1000 of population



Month


Transfusion triggers for adults

Revised 2014

Patient status	Transfusion threshold
Healthy patient < 65 yr	Hb < 70 g/l
Healthy patient > 65 yr	Hb < 80 g/l
Cardiovascular disease	Hb < 90 g/l
Bone marrow suppression	Hb < 90 g/l
Chemo or Radiotherapy	Hb < 90 g/l
Sig. symptoms / signs of anaemia	Hb < 100 g/l
Active major bleeding	Hb < 100 g/l

Avoid over transfusion: Hb > 20g/l above target threshold

Platelet issues



Summary

- Steady decline in red cell transfusion index last 10 years
- Contributing factors include:
 - Audit process
 - Regional transfusion triggers
 - Regional guidance on management of anaemia
 - Stakeholder involvement
- Endorsement by Department of Health

Acknowledgements

- NITC Members
- Haemovigilance Team, Shirley Murray
- Hospital Transfusion Committees
- Hospital Blood Banks
- CMO, DoH Advisory Committee
- Prof. Mike Murphy